News

Veeva Partners with Amgen to Revolutionize Clinical Trials

Veeva Partners with Amgen to Revolutionize Clinical Trials

Veeva and Amgen Join Forces for Clinical Trial Advancement

In a remarkable step towards enhancing clinical trial efficiency, Veeva Systems (NYSE: VEEV) has announced an exciting collaboration with Amgen, a notable leader in the biotech industry. This partnership aims to leverage the immense potential of the Veeva Clinical Platform to optimize and innovate the clinical trial process. With an aim to expedite the development of new medicines for patients facing serious health conditions, this collaboration marks a significant milestone for both organizations.

Enhancing Clinical Development Through Technology

Scott Skellenger, the senior vice president and chief information officer at Amgen, expressed enthusiasm about the partnership, stating, "In collaboration with Veeva, we're leveraging advanced technology to unlock new capabilities for our end-to-end trial operations. This is expected to enhance our ability to deliver innovative treatments to patients swiftly and at scale." This forward-thinking approach ensures that trials are not only more effective but also more responsive to the demands of modern healthcare.

Understanding the Veeva Clinical Platform

The Veeva Clinical Platform serves as a comprehensive and integrated solution for clinical operations and data applications. This end-to-end platform encompasses various functionalities including Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Randomization and Trial Supply Management (RTSM), among others. By streamlining the clinical trial process from study initiation to conclusion, Veeva offers a robust framework that promotes a seamless data flow across various stages of clinical development.

Impact on the Healthcare Sector

With the integration of Veeva's Clinical Platform, the partnership aims to facilitate a more efficient clinical trial ecosystem. Jim Reilly, president of Veeva Development Cloud, emphasized the importance of this collaborative effort, stating, "We’re excited to help Amgen further advance clinical development. Veeva Clinical Platform will provide the backbone for standard and connected processes that can speed the delivery of life-saving drugs to patients in need."

Support and Implementation from Veeva Business Consulting

Part of this strategic alliance includes the support from Veeva Business Consulting, which will assist Amgen through both the implementation process and change management. This ensures that Amgen can seamlessly adopt the new systems and methodologies necessary for optimizing their clinical trials.

A Commitment to Innovation

Veeva Systems continues to be a key player in the life sciences industry, delivering cutting-edge software, data solutions, and business consulting services tailored specifically for life sciences. The company prides itself on its dedication to innovation and excellence, serving over 1,500 clients that include the world’s largest biopharmaceutical companies alongside emerging biotech firms. This collaboration with Amgen is yet another testament to Veeva's mission of facilitating the development of groundbreaking therapies that ultimately benefit patients across the globe.

Why This Collaboration Matters

The successful integration of the Veeva Clinical Platform could pave the way for a transformation in the clinical trial landscape, making it crucial for biopharmaceutical firms striving for quicker patient access to innovative treatments. As the healthcare industry evolves, partnerships like these are essential in fostering a culture of collaboration and technological advancement, all aimed at improving patient outcomes.

Frequently Asked Questions

What is the main goal of the collaboration between Veeva and Amgen?

The main goal is to leverage advanced technology to enhance clinical trial operations and accelerate the development of new treatments for patients.

What does the Veeva Clinical Platform offer?

It provides a comprehensive solution including functionalities such as CTMS, EDC, RTSM, and a connected data flow to streamline clinical trials.

How will Veeva Business Consulting support Amgen?

Veeva Business Consulting will assist Amgen during the implementation and change management processes associated with adopting the Veeva Clinical Platform.

What impact will this collaboration have on patients?

This collaboration aims to speed up the delivery of life-saving medications and enhance the overall clinical trial process, leading to quicker patient access to innovative treatments.

Why is Veeva an important player in the life sciences industry?

Veeva serves more than 1,500 customers with a commitment to innovation and excellence, making it a pivotal company for biotech and biopharmaceutical development.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Findings on gMG Treatments by UCB at AANEM 2024

Updated Category News Views 127

UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...

Continue Reading
Lysander Funds Shares New Distributions Estimates for ETFs

Updated Category News Views 131

Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...

Continue Reading
Empowering Girls: Pace Center's Initiatives for Growth

Updated Category News Views 350

Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...

Continue Reading
Bank of America Sees Growth in Loans, Deposits Amid Profit Rise

Updated Category News Views 284

Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...

Continue Reading
Investigating Manitex International: A Closer Look at MNTX

Updated Category News Views 72

Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...

Continue Reading